About the Mammary Fold Academic Sub-Commiteee
Paralleling the development of the ABS Academic & Research Committee, 2012 saw the development of the Mammary Fold Academic Sub-Committee (MFAC). Our aim was to develop a national research collaborative that may facilitate local trainee group projects, as well as design and conduct novel studies looking at current practice.
For a list of Academic Sub-Committee members please click here.
To find out more about becoming a member of the Academic Sub-Commitee please contact email@example.com.
The aims of the Mammary Fold Academic & Research Commitee are:
- To enhance care and outcome for patients with breast disease through promoting and supporting trainee-led audit and research
- To develop a national collaborative to facilitate high quality trainee-led audit and research projects, as well as design and conduct novel studies
Each year, approximately 51,000 women will be diagnosed with breast cancer, of which up to 40% may require a mastectomy. This may impact on a woman’s quality of life and body image and, in the UK, immediate breast reconstruction (IBR) is routinely offered to improve outcomes.
Complication rates following immediate breast reconstruction may have a significant impact, as this may lead to the delay or omission of adjuvant chemo and/or radiotherapy. The clinical significance of these short delays remains unclear, but studies have demonstrated an adverse impact on recurrence free and overall survival. A 2013 meta-analysis suggests a 15% decrease in overall survival for every four week delay in the delivery of adjuvant chemotherapy.
iBRA-2 is a national multi centre prospective audit which aims to evaluate the impact of immediate breast reconstruction on the time to adjuvant therapy compared with mastectomy alone.
For more information about the iBRA2 study please click here to download the poster. You can also download a guide for local study leads by clicking here or the iBRA2 protocol here. Data collection sheets can be downloaded here. If you have a question about the iBRA2 study or would like additional information, please email firstname.lastname@example.org.
Therapeutic mammaplasty (TM) extends the boundaries of breast-conserving surgery by combining breast reduction and mastopexy techniques with tumour excision, preserving a natural breast shape and avoiding the need for mastectomy in some patients. In recent years the technique has rapidly grown in popularity in the UK, however, its current prevalence and success rate are unknown. Furthermore, there is a lack of robust evidence in the literature to support the technique. The TeaM study is a multicentre prospective audit that aims to describe the practice and outcomes of TM, measuring against ABS and BAPRAS standards where applicable. The study uses a research collaborative model involving both breast and plastic surgeons. Anonymised data is collected using REDCap and includes patient demographics, tumour characteristics, operative details, pathology, post-operative outcomes and 30 day complications. Projected recruitment is 500 patients, data collection started in September 2016 and will end on 30th June 2017. It is anticipated to be the largest study of TM worldwide to date.
You can download the TeaM Audit proposal and protocol by clicking here. If you are a local study lead please click here to download the TeaM guide for local study leads and TeaM data collection sheets. Please contact email@example.com if you would like further information.